A Kinetic Model for the Metabolic Interaction of Two Substrates at the Active Site of Cytochrome P450 3A4*

In many cases, CYP3A4 exhibits unusual kinetic characteristics that result from the metabolism of multiple substrates that coexist at the active site. In the present study, we observed that α-naphthoflavone (α-NF) exhibited a differential effect on CYP3A4-mediated product formation as shown by an increase and decrease, respectively, of the carboxylic acid (P2) and ω-3-hydroxylated (P1) metabolites of losartan, while losartan was found to be an inhibitor of the formation of the 5,6-epoxide of α-NF. Thus, to address this problem, a kinetic model was developed on the assumption that CYP3A4 can accommodate two distinct and independent binding domains for the substrates within the active site, and the resulting velocity equations were employed to predict the kinetic parameters for all possible enzyme-substrate species. Our results indicate that the predicted values had a good fit with the experimental observations. Therefore, the kinetic constants can be used to adequately describe the nature of the metabolic interaction between the two substrates. Applications of the model provide some new insights into the mechanism of drug-drug interactions at the level of CYP3A4.

[1]  L. Wienkers,et al.  Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+). , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[2]  R. Miller,et al.  Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[3]  J. Halpert,et al.  Dual role of human cytochrome P450 3A4 residue Phe-304 in substrate specificity and cooperativity. , 2000, The Journal of pharmacology and experimental therapeutics.

[4]  G. Miller,et al.  Elucidation of distinct ligand binding sites for cytochrome P450 3A4. , 2000, Biochemistry.

[5]  Renke Dai,et al.  Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site , 1999 .

[6]  J. Halpert,et al.  Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  A. Rettie,et al.  Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. , 1998, Biochemistry.

[8]  J. Liu,et al.  Analysis of four residues within substrate recognition site 4 of human cytochrome P450 3A4: role in steroid hydroxylase activity and alpha-naphthoflavone stimulation. , 1998, Archives of biochemistry and biophysics.

[9]  A Carlsson,et al.  Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. , 1997, Life sciences.

[10]  A. P. Koley,et al.  Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.

[11]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[12]  Susan E. Wilson,et al.  Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E‐3174 , 1996, Clinical pharmacology and therapeutics.

[13]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[14]  S. Waldman,et al.  Losartan Does Not Affect the Pharmacokinetics and Pharmacodynamics of Warfarin , 1995, Journal of clinical pharmacology.

[15]  H. Yamazaki,et al.  Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. , 1995, Chemical research in toxicology.

[16]  P. Chakravarty,et al.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[17]  F. Guengerich,et al.  Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[18]  M. Waterman,et al.  Assessment of the Use of Single Cytochrome P450 Enzymes in Drug Research , 1994, Ernst Schering Research Foundation Workshop.

[19]  R. Brodell,et al.  A practical approach to antibiotic treatment in women taking oral contraceptives. , 1994, Journal of the American Academy of Dermatology.

[20]  S. Sligar,et al.  Cytochrome P450 and Aromatic Bases: A 1H NMR Study , 1994 .

[21]  D. Kroetz,et al.  Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. , 1994, Biochemical pharmacology.

[22]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[23]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[24]  R. Woosley,et al.  Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.

[25]  S. Imaoka,et al.  Role of phospholipids in reconstituted cytochrome P450 3A form and mechanism of their activation of catalytic activity. , 1992, Biochemistry.

[26]  T. Shimada,et al.  Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. , 1992, Chemical research in toxicology.

[27]  S. Nelson,et al.  Activation of acetaminophen-reactive metabolite formation by methylxanthines and known cytochrome P-450 activators. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[28]  P. Timmermans,et al.  Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. , 1990, The Journal of pharmacology and experimental therapeutics.

[29]  G. Lucier,et al.  Involvement of cytochrome P-450c in alpha-naphthoflavone metabolism by rat liver microsomes. , 1990, Molecular pharmacology.

[30]  F. Gonzalez,et al.  The molecular biology of cytochrome P450s. , 1988, Pharmacological reviews.

[31]  E. Johnson,et al.  Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. , 1988, Molecular pharmacology.

[32]  F. Guengerich Oxidation of 17 alpha-ethynylestradiol by human liver cytochrome P-450. , 1988, Molecular pharmacology.

[33]  J. Kellis,et al.  Inhibition of human estrogen synthetase (aromatase) by flavones. , 1984, Science.

[34]  P. Beaune,et al.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. , 1983, Biochemistry.

[35]  M. J. Coon,et al.  Specificity in the activation and inhibition by flavonoids of benzo[a]pyrene hydroxylation by cytochrome P-450 isozymes from rabbit liver microsomes. , 1981, The Journal of biological chemistry.

[36]  M. Huang,et al.  Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. , 1981, The Journal of biological chemistry.

[37]  H. Bolt,et al.  Interaction of rifampicin treatment with pharmacokinetics and metabolism of ethinyloestradiol in man. , 1977, Acta endocrinologica.

[38]  Y. Yasukochi,et al.  Some properties of a detergent-solubilized NADPH-cytochrome c(cytochrome P-450) reductase purified by biospecific affinity chromatography. , 1976, The Journal of biological chemistry.

[39]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1976 .

[40]  D. Marquardt An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[41]  T. Shimada,et al.  The Importance of Cytochrome P450 3A Enzymes in Drug Metabolism , 1994 .

[42]  Benveniste,et al.  Cytochrome P450 , 1993, Handbook of Experimental Pharmacology.

[43]  C. F. Timberlake The Flavonoids—Advances in Research since 1980: : edited by J. B. Harborne. Chapman & Hall, London and New York, xiii+621 pp. £95. , 1989 .

[44]  R. Stewart,et al.  Clinically desirable drug interactions. , 1985, Annual review of pharmacology and toxicology.

[45]  P. Richardson The Flavonoids: Advances in Research , 1982 .

[46]  F. Wedler Enzyme kinetics: Behavior and analysis of rapid equilibrium and steady‐state enzyme systems. Author: Irwin H. Segal (University of California, Davis). Published by Wiley‐Interscience, New York, 1975. Price: $24.50. No. of pages: 957 , 1976 .